CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To assess the effect of the drugs on an additional potential surrogate marker for in vivo clinical drug response, we analyzed whether the treatments might also inhibit the colony forming capacity of CD34+ stem/progenitor cells isolated from six CML patients at diagnosis (Fig. 8 and Supplementary Fig. 3B, left panels).